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Abstract
Background:  In addition to its essential role in ribonucleotide reduction, ribonucleotide
reductase (RNR) small subunit, RRM2, has been known to play a critical role in determining tumor
malignancy. Overexpression of RRM2 significantly enhances the invasive and metastatic potential of
tumor. Angiogenesis is critical to tumor malignancy; it plays an essential role in tumor growth and
metastasis. It is important to investigate whether the angiogenic potential of tumor is affected by
RRM2.
Results:  We examined the expression of antiangiogenic thrombospondin-1 (TSP-1) and
proangiogenic vascular endothelial growth factor (VEGF) in two RRM2-overexpressing KB cells:
KB-M2-D and KB-HURs. We found that TSP-1 was significantly decreased in both KB-M2-D and
KB-HURs cells compared to the parental KB and mock transfected KB-V. Simultaneously, RRM2-
overexpressing KB cells showed increased production of VEGF mRNA and protein. In contrast,
attenuating RRM2 expression via siRNA resulted in a significant increased TSP-1 expression in both
KB and LNCaP cells; while the expression of VEGF by the two cells was significantly decreased
under both normoxia and hypoxia. In comparison with KB-V, overexpression of RRM2 had no
significant effect on proliferation in vitro, but it dramatically accelerated in vivo subcutaneous
growth of KB-M2-D. KB-M2-D possessed more angiogenic potential than KB-V, as shown in vitro
by its increased chemotaxis for endothelial cells and in vivo by the generation of more vascularized
tumor xenografts.
Conclusion: These findings suggest a positive role of RRM2 in tumor angiogenesis and growth
through regulation of the expression of TSP-1 and VEGF.
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Background
Ribonucleotide reductase (RNR) plays an essential role in
catalyzing conversion of ribonucleoside diphosphates to
the corresponding 2'-deoxyribonucleoside diphosphates,
a rate-limiting step in the production of 2'-deoxyribonucl-
eoside 5'-diphosphates (dNTP) required for DNA synthe-
sis and repair [1]. Human ribonucleotide reductase
consists of two subunits: RRM1 and RRM2, both proteins
are required for enzymatic activity. The cellular RRM1
protein level remains relatively stable throughout the
entire cell cycle, whereas RRM2 is only expressed during
the late G1/early S phase, and degraded in late S phase.
The activity of RNR, and therefore DNA synthesis and cell
proliferation, is controlled during the cell cycle by the syn-
thesis and degradation of RRM2 subunit [2]. RRM2 itself
is a dimmer of two 44 kDa moieties, each containing non-
heme iron that stabilizes a unique tyrosyl-free radical
required for enzyme activity [3]. Recently cloned p53R2, a
new RNR family member, encodes a protein with striking
similarity to RRM2, which is induced by UV light, γ-irradi-
ation or adriamycin in a wild type p53-dependent manner
[4]. p53R2 directly participates in p53-directed repair of
damaged DNA through generating a RNR holoenzyme
with RRM1 to synthesize the dNTPs for DNA repair [5].
Many studies have demonstrated that increased RNR
enzymatic activity is tightly associated with tumor pro-
gression and malignancy. Alteration in the activity of RNR
has been identified in a variety of tumor cells obtained
from mouse and human tissues [6-8]. Apart from the well-
known role in ribonucleotide reduction, several studies
have indicated that RRM1 and RRM2 may play opposite
roles in controlling malignant progression of tumor cells.
Studies had identified that overexpression of both mice
R1 and human RRM1 significantly inhibited in vivo tumor
growth and decreased metastatic potential of tumor
through activating PTEN pathway [9-11]. Conversely,
overexpression of mouse R2 markedly enhanced cellular
transforming potential of various oncogenes; and
increased malignant potential of transformed cells [11-
13]. We and others had reported that overexpression of
human RRM2 could enhance the invasive and metastatic
potential of various human cancer cells [14-16]. Our
recent study had also shown that the RRM2 protein level
in human colon cancer was positively correlated to the
metastasis of colon cancer, and elevated RRM2 may serve
as a potential biomarker for metastasis of colon cancer
[8,14].
Angiogenesis, the formation of new blood vessel from
pre-existing vessel, plays a critical role in many physiolog-
ical and pathological conditions including embryonic
development, wound healing, tumor growth and metasta-
sis [17,18]. Angiogenesis is tightly controlled by a balance
of pro-angiogenic and anti-angiogenic factors [19].
Among many angiogenesis factors, vascular endothelial
growth factor (VEGF) is one of the most critical and spe-
cific factors that stimulate both physiological and patho-
logical angiogenesis; the expression of VEGF are induced
by growth factors and hypoxia [20]. Whereas, among
many antiangiogenic factors, thrombospondin-1 (TSP-1)
is a very potent angiogenesis inhibitor, and down-regula-
tion of TSP-1 has been suggested to alter tumor growth by
modulating angiogenesis in a variety of tumor types [21].
Oncogenes activation and loss of tumor suppressor genes
activity can directly regulate the expression of proang-
iogenic and antiangiogenic factors in an opposite way
thus determining the overall angiogenic activity of tumors
[22]. In tumor cells, VEGF is also stimulated by mutated
ras, v-src, c-fos and c-jun etc [22]. The expression of TSP-1
is upregulated by the tumor suppressor gene, p53, and
down-regulated by oncogenes such as myc and ras [20-
22].
Tumor angiogenesis is a hallmark of malignancy; it plays
an essential role in tumor growth and metastasis [23].
However, the implication of the RRM2 in tumor angio-
genesis is not closely studied. Therefore, in the present
study, we examined the impact of the RRM2 on tumor
angiogenesis through its regulating the expression of
proangiogenic factor VEGF, and antiangiogenic factor
TSP-1. For the first time, we found overexpression of
RRM2 alone reduces TSP-1 expression; induced VEGF
expression in tumor cells, resulted in a tumor xenograft
with more angiogenic potential and accelerated growth in
vivo. Our results indicate a positive role of RRM2 in tumor
angiogenesis and progression.
Methods
Cell Culture
Human oropharyngeal carcinoma KB cells (American
Type Culture Collection, Manassas, VA), were cultured in
a 5% CO2 atmosphere at 37°C on plastic tissue culture
plates in DMEM supplemented with 10% fetal bovine
serum and 1% penicillin/streptomycin. RRM2-overex-
pressing KB-M2-D and the mock-transfected KB-V were
cultured in the same medium of KB cells with 300 μg/ml
G-418 [15]. KB-HURs, a hydroxyurea-resistant clone with
an elevated RRM2 protein induced by hydroxyurea, was
incubated and maintained in the presence of 1 mM
hydroxyurea [15] as another RRM2-overexpressing cells
clone in this study. The human prostate adenocarcinoma
LNCaP was cultured in RPMI1640 medium containing
10% heat-inactivated fetal bovine serum (FBS; Gibco BRL,
Grant Island, NY, USA) and 1 mM sodium pyruvate. For
cell culture under hypoxia, cells were grown in a chamber
containing 1% O2, 5% CO2 and 94% N2 at 37°C.
Quantitative reverse transcriptional PCR: q-RT-PCR
Total RNA was extracted from cells by using of Qiagen
RNeasy Min Kit. Residual genomic DNA was removed by
incubating the RNA with DNase (Qiagen, Valencia, CA).Molecular Cancer 2009, 8:11 http://www.molecular-cancer.com/content/8/1/11
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cDNA was synthesized from 1.0 μg of total RNA using the
Superscript III first-strand cDNA synthesis kit (Invitrogen,
Carlsbad, CA) in a final volume of 20 μl with 0.25 μg ran-
dom hexamer and 200 Units of Superscript RNase H-
reverse transcriptase. The reaction mixture was firstly incu-
bated at 25°C for 5 min, and then followed by incubation
at 50°C for 50 min. Quantitative real time PCR was car-
ried out in the ABI Prism 7900 HT Sequence Detection
System (Applied Biosystems, Foster City, CA). The reac-
tion mixture of 20 μl consisted of 1× ABI SYBR Green PCR
Master Mix, 0.25 μl cDNA and 0.2 μM of each primer. The
PCR protocol was: 95°C for 10 min, followed by 40 cycles
of 95°C for 15 s, 60°C 1 min. The following primers were
used: RRM2, 5'-GCGATTTAGCCAAGAAGTTCAGAT-3'
(forward) and 5'-CCCAGTCTGCCTTCTTCTTGA-3'
(reverse); TSP-1, 5'-ACGAGGAATGGACTGTTGATAGC-3'
(forward) and 5'-ATCAGGAACTGTGGCATTGGAG-3'
(reverse). VEGF, 5'-CCAGCACATAGGAGAGATGAGCTT-
3' (forward) 5'-TCTTTCTTTGGTCTGCATTCACAT-3'
(reverse). Beta-Actin, 5'-ATCTGGCACCACACCTTCTA-
CAA-3' (forward) 5'-GTACATGGCTGGGGTGTTGAAG-3'
(reverse).
Relative gene-expression quantification method was used
to calculate the fold change of mRNA expression accord-
ing to the comparative Ct method using β-actin as an
endogenous control. Final results were determined as fol-
lows: 2-(ΔCt sample-ΔCt control), where ΔCt values of the control
and sample were determined by subtracting the Ct value of
the target gene from the value of the housekeeping gene:
β-actin. Data was represented as ratio or folds change to
control sample.
RRM2 siRNA Knockdown assay
The human RRM2 gene specific siRNA (sc-36338) and
scramble siRNA were purchased from Santa Cruz Biotech-
nology, Inc. (Santa Cruz, CA). 5 × 105/well KB cells were
cultured in six-well plates with 2-mL antibiotic-free
growth medium at 37°C in a CO2 incubator for 24 hours.
siRNA duplex-Lipofectamine was prepared by 6.0 μL of 10
μmol/L RRM2 siRNA or scramble siRNA and 3.0 μl Lipo-
fectamine RNAiMAX (Invitrogen, Carlsbad, CA) in 500 μl
serum-free OptiMEM medium (Invitrogen, Carlsbad, CA)
according to the manufacturer's instructions, and directly
added into the media. 24 or 48 h after transfection, cells
was collected [8]. The knockdown of RRM2 was measured
by quantitative reverse transcription-PCR (q-RT-PCR) and
Western blot.
Preparation of conditioned medium and ELISA assay
Cells were seeded in 35 mm dishes in 2 ml of growth
medium to reach approximately 80% confluence. Cells
were washed with PBS 3 times and then were either cul-
tured for 24 h under normoxic or hypoxic condition in 2
ml of serum free medium at 37°C. Cell supernatants were
collected, clarified by centrifugation at 2000 rpm for 5
min, and stored at -80°C. Concomitantly, the cell pellets
were used in parallel for RT-PCR and total protein concen-
tration. Condition medium for samples of RRM2 knock-
down was collected as following. Firstly, cells were
cultured in complete medium for 24 h post-transfection
under normoxia. Then, cells were further cultured in
serum free medium for 24 h under either normoxia or
hypoxia (1% O2), and the medium was collected. The
amount of VEGF in condition medium was measured
with a QuantikineTM immunoassay kit (VEGF-ELISA
R&D system, Minneapolis, MN, USA) following the man-
ufacturer's instructions. VEGF was expressed as ng of
VEGF protein/ml of medium and per mg of total protein.
Western blot analysis
The mouse monoclonal antibodies against Beta-Actin,
RRM2, were obtained from Santa Cruz Biotechnology
(Santa Cruz, CA). Mouse monoclonal antibody against
human TSP-1 was purchased from Thermo Scientific (Fre-
mont, CA). Western blot was conducted as previously
described [8]. Briefly, about 20-μg total protein was sepa-
rated by 10% SDS-PAGE, transferred to a Nitrocellulose
membrane (Bio-Rad Laboratories, CA) and incubated in
blocking buffer (1% I-Block reagent and 0.1% Tween 20)
with the primary antibody (1:1000 dilution) overnight at
4°C. After 3–5 washes, the membrane was incubated with
fluorescent-labeled secondary antibodies (1:8,000 dilu-
tions) for 60 minutes. After sequential washes, mem-
branes were scanned on an Odyssey Infrared Imaging
System (LI-COR Biosciences). Signals were densitometri-
cally assessed and normalized to the β-actin signals.
Human umbilical vein endothelial cell migration assay
Modified Boyden chambers (Millicell PCF, 8 μm pore
size; Millipore) were placed in a 24-well plate and coated
with 10 μg/ml collagen I (Roche Diagnostics) overnight.
After washing with PBS, 0.6 ml of concentrated condition
media was placed in the bottom chamber. HUVEC cells
were cultured in complete EBM-2 medium (Cambrex Bio-
science, MD, USA), and passage 5–6 of HUVEC was used
for the experiment. After starvation for 16 h, 2 × 105
human umbilical vein endothelial cells (HUVEC) were
resuspended in 0.3 ml DMEM/0.1% BSA, plated in the
top of the transwell chambers, and incubated for 24 h at
37°C with 5% CO2. Cells were removed from the upper
membrane surface with a cotton tip applicator, washed
with PBS, and cells on the lower membrane surface were
fixed and stained (Hema 3 Stain System; Fisher Diagnos-
tics). HUVEC migration was quantified by manually
counting the number of cells on the inserts under high-
power at ×100 magnification. The migration of HUVEC
added to the upper compartment of the chamber, was
expressed as the number of cells migrated in 10 high-
power fields. Values were expressed as the mean ± SD ofMolecular Cancer 2009, 8:11 http://www.molecular-cancer.com/content/8/1/11
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two independent tests; each test included three individual
wells [24].
In vitro proliferation and in vivo growth
0.5 × 104 of KB-V and KB-M2-D cells were replated into
wells of 16-well devices compatible with a W200 real-time
cell electronic sensing (RT-CES) analyzer and 16× station
(Acea Biosciences, San Diego, CA). Cell growth was mon-
itored periodically (typically, every 0.5 or 1 h) for indi-
cated durations via calculation of a "cell index"
(normalized impedance) for each well. Unless otherwise
indicated, cells from each well of the original six-well
plates were replated into four replicate wells for cell index
measurement.
The animal protocol for tumorigenicity assay in vivo was
approved by the Institutional Animal Care and Use Com-
mittee of City of Hope Medical Center with RACC proto-
col number 0750. 6 to 8t-week-old Nod-Scid mice (City of
Hope) were subcutaneously inoculated in the right flank
with either 5 × 106 KB-V or KB-M2-D cells resuspended in
100  μL serum-free RPMI. Tumor xenografts appeared
approximately 3–6 days following cell injection. Tumor
xenograft diameters were measured with digital calipers
twice a week, and the tumor volume in mm3 was calcu-
lated by the formula: Volume = (width)2 × length/2; and
results were presented as mean tumor volume ± SD of two
independent experiments. Mouse was sacrificed on 30th
day after inoculation. Tumor xenografts were dissected
and the final volume and wet weight were determined.
Subsequently, they were cut through the median, one part
was fixed in formalin and embedded in paraffin, the other
part was embedded in Tissue-Tek and snap frozen in liq-
uid nitrogen.
Immonostainig IHC Microvessel analysis
For immunohistochemical analysis of CD31 (a specific
marker of endothelial cells), formalin fixed and paraffin
embedded tumor sections were permeabilized with 36
μg/ml proteinase K and stained with a rat anti-mouse
CD31 antibody (clone MEC13.3, BD Biosciences), final
dilution 1:250. Tyramide signal amplication kits (Perk-
inElmer Life and Analytical sciences, Inc.) were used with
Cyanine 3 red fluorescence. Microvessel density was qual-
itatively assessed by examining the entire vital cellular
zone of the tumors according to the described procedure
[25]. Microvessel count was carried out on three fields
(×100) chosen within the whole vascularized areas. Any
endothelial cell or cluster of endothelial cells positive for
CD31 was counted.
Statistics
Data were collected using an MS-Excel spreadsheet. Data
were analyzed using the JMP Statistical Discovery Soft-
ware version 6.0 (SAS Institute, Cary, NC). Group com-
parisons for continuous data were done with student's t-
test for independent means or two-way ANOVA. Statisti-
cal significance was set at P < 0.05.
Results
Overexpression of RRM2 decreased TSP-1 expression in 
KB Cells
Two human oropharyngeal carcinoma KB cell lines: KB-
M2-D, which was forced to overexpress RRM2 protein by
gene transfer, and KB-HURs, which was induced to over-
express RRM2 protein by hydroxyurea, were established as
reported previously [15]. Overexpression of RRM2 in
these two cells was confirmed at both protein (Figure 1a,
b) and mRNA level (Figure 1c, P < 0.01). The levels of
RRM1 (the large subunit of RNR) and p53R2 (the small
subunit homologue of RRM2) were not significantly
changed in KB-M2-D and KB-HURs as indicated by West-
ern blot analysis (Figure 1a). To answer whether overex-
pression of RRM2 had a positive effect on tumor
angiogenesis, we firstly determined the effect of overex-
pression of RRM2 on the production of well known pro-
and anti-angiogenic factors.
Among many anti-angiogenic factors, TSP-1 is a very crit-
ical angiogenic inhibitor; it can directly inhibit endothe-
lial cell migration and proliferation [21,24]. We examined
the protein levels of TSP-1 in total protein extracts (abbre-
viated as TSP1-T in Figure 1a) and equally concentrated
condition mediums (abbreviated as TSP1-CM in Figure
1a) from KB, KB-V, KB-M2-D, and KB-HURs. Western-blot
analysis displayed that both RRM2-overexpressing KB-
M2-D, and KB-HURs cells showed a dramatic decrease in
TSP-1 protein compared to control KB and KB-V cells (Fig-
ure 1a, b). To investigate whether the decreased TSP-1 pro-
tein was due to reduced synthesis at mRNA level, we also
measured by q-RT-PCR the TSP-1 mRNA levels in cells.
We found, in both RRM2-overexpressing cells, the TSP-1
mRNA levels were significantly decreased (Figure 1d, P <
0.01).
Overexpression of RRM2 increased VEGF expression in KB 
Cells
VEGF is a key mediator of tumor-associated angiogenesis
and is thought to support neovascularization by inducing
endothelial cell migration and proliferation leading to
vascular permeability [18-20]. To answer whether overex-
pression of RRM2 also effects on VEGF expression in can-
cer cells, we examined the levels of VEGF in the condition
medium of KB cells. By ELISA assay, we found that RRM2-
overexpressing KB-M2-D and KB-HURs released about
2.8-fold and 2.2-fold more VEGF than control cells (Fig-
ure 2a, P < 0.05). The induction of VEGF expression could
be regulated at the level of either mRNA or protein. Meas-
ured by Q-RT-PCR, we found that in the two RRM2-over-
expressing cells VEGF mRNA was significantly increasedMolecular Cancer 2009, 8:11 http://www.molecular-cancer.com/content/8/1/11
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(Figure. 2b, P < 0.01). Hypoxia condition in tumor has
been shown to be an important stimulus for VEGF gene
expression as well as tumor angiogenesis. To determine
the effect of RRM2 on VEGF expression under hypoxia, we
compared VEGF mRNA and protein in KB-V and KB-M2-
D cells. The results showed that hypoxia (1% oxygen for
16h) upregulated VEGF by ~2 fold at protein levels (Fig-
ure. 2c, P < 0.05) or ~4-fold at mRNA (Figure. 2d, P <
0.01) in both cells. Compared with that of KB-V, the pro-
duction of VEGF in KB-M2-D was still significantly higher
under both normoxia and hypoxia (Figure. 2c, d, P  <
0.05).
Knockdown of RRM2 increased TSP-1 and decreased VEGF 
expression in both KB and LNCaP Cells
Overexpression of RRM2 significantly decreased TSP-1,
simultaneously increased VEGF expression in KB cells. To
further confirm the implication of RRM2 in the regulation
of TSP-1 and VEGF expression, we measured TSP-1 and
VEGF expression level, after RRM2 in cancer cells was
Overexpression of RRM2 decreased TSP-1 expression in KB-M2-D and KB-HURs cells Figure 1
Overexpression of RRM2 decreased TSP-1 expression in KB-M2-D and KB-HURs cells. (A) Western blot analysis 
confirmed that only RRM2 was overexpressed in KB-M2-D and KB-HURs; the expression of RRM1 and p53R2 was not signifi-
cantly modulated in both KB-M2-D and KB-HURs; and the expression of TSP-1 was significantly decreased in KB-M2-D and 
KB-HURs cells by 60%~70% (TSP1-CM: TSP-1 in concentrated condition medium, TSP1-T: TSP-1 in total protein). (B) Repre-
sentative quantitative densitometric analysis of RRM2 and TSP-1 expression. Signal intensities were normalized to that of β-
actin serving as loading control; data was presented as fold of KB. (C) q-RT-PCR analysis confirmed that RRM2 mRNA was 
dramatically overexpressed in KB-M2D and KB-HURs compared with parental KB (**p < 0.01). Values of q-RT-PCR were the 
mean ± SD of three independent experiments and presented as ratio to the level of parental KB cells. (D) q-RT-PCR analysis 
showed TSP-1 mRNA was significantly decreased in KB-M2D and KB-HURs compared with parental KB (**p < 0.01).Molecular Cancer 2009, 8:11 http://www.molecular-cancer.com/content/8/1/11
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knocked down by its specific siRNA. Q-RT-PCR and West-
ern blot analysis showed that RRM2 mRNA and protein in
KB cells was significantly decreased at 48 h post-transfec-
tion of siRNA (Figure 3a, b). RRM2 level at 24 h and 72 h
post-transfection of siRNA was also significantly
decreased (data not shown). Simultaneously, we meas-
ured TSP-1 expression in KB cells, we found TSP-1 mRNA
and protein was significantly upregulated at all three
points (Figure 3a, b, P < 0.05). By using of q-RT-PCR anal-
ysis, we confirmed under both normoxia and hypoxia
RRM2 mRNA in KB cells was significantly decreased by
siRNA transfection (Figure 3c, P < 0.01). And knockdown
of RRM2 in KB cells moderately decreased VEGF mRNA
and protein expression under normoxia, significantly
decreased VEGF expression under hypoxia (Figure 3d and
3e, P < 0.05).
It is important to address whether the regulation of RRM2
on TSP-1 and VEGF expression is a cell specific response
or not. To answer this question, we then measured the
effect of the knockdown of RRM2 on VEGF and TSP-1
expression in human prostate cancer cell: LNCaP, which
also contains a wild-type p53. Similar to the change in KB
cells, knockdown of RRM2 also significantly increased
Overexpression of RRM2 increased VEGF expression in KB-M2-D and KB-HURs cells Figure 2
Overexpression of RRM2 increased VEGF expression in KB-M2-D and KB-HURs cells. (A) VEGF in condition 
mediums of KB-M2-D and Kb-HURs were increased by 2.4-fold and 2.1-fold respectively. Levels of VEGF in the condition 
medium were measured with ELISA. Data, presented as ng of VEGF protein/ml of medium and per mg of total protein, was the 
mean ± SD of 2–3 preparation. (B) q-RT-PCR analysis showed that VEGF mRNA was increased in KB-M2D and KB-HURs by 
3~4 fold compared with parental KB and KB-V cells. (C) Compared with KB-V, KB-M2-D secreted more VEGF under both 
normoxia and hypoxia. (D) q-RT-PCR analysis showed KB-M2D expressed more VEGF mRNA than KB-V under both nor-
moxia and hypoxia, *p < 0.05, **p < 0.01 compared with KB-V.Molecular Cancer 2009, 8:11 http://www.molecular-cancer.com/content/8/1/11
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TSP-1 mRNA and protein (Figure 4a, b, P < 0.05). Knock-
down of RRM2 in LNCaP cells (Figure 4c, P < 0.01) signif-
icantly decreased VEGF mRNA and protein under both
normoxia and hypoxia conditions (Figure 4d, e, P < 0.05).
The decreased VEGF in LNCaP was more pronounced
under hypoxia condition. The data indicates that the reg-
ulation of RRM2 on TSP-1 and VEGF may not be a cell
type specific but a common event; and a common mech-
anism may responsible for this regulation.
RRM2-overexpressing KB-M2-D cells showed accelerative 
tumor growth in vivo
In order to determine whether overexpression of RRM2
had an effect on cell in vitro proliferation in KB cells, RT-
CES cell proliferation assays (Acea Biosciences, San Diego,
CA) were performed with KB-V and KB-M2D. RT-CES
traces displayed that proliferation of KB-M2-D did not
demonstrated significant differences with that of control
KB-V over a period of 72 h (Figure 5a). Next, we assessed
the effect of RRM2 on tumor in vivo growth. The KB-V and
KB-M2-D were inoculated subcutaneously in the hind
flank of non-SCID mice. The tumor xenografts were meas-
ured on a regular basis for 30 days. We found ~5–6 days
after inoculation the growth of KB-M2-D xenograft begun
to display a significant larger mass than that of xenografts
KB-V (Figure 5b, P < 0.05). Correspondingly, compared
with that of KB-V, the average weight of KB-M2-D
xenografts was also significantly increased by ~50% (Fig-
ure 5c, P < 0.01). q-RT-PCR analysis confirmed that the
expression of RRM2 and VEGF was significantly higher in
KB-M2-D xenografts than these in KB-V xenografts, TSP-1
in KB-M2-D xenografts was significantly lower (Figure 5d,
P < 0.01). Those data confirmed that overexpression of
RRM2 promotes cancer cells in vivo growth.
Overexpression of RRM2 promoted angiogenic potential 
of tumors in vitro and in vivo
Tumor angiogenesis is controlled by a balance of pro-ang-
iogenic and anti-angiogenic factors [18-20]. We ques-
tioned whether the increased production of angiogenic
factors VEGF and the parallel reduction of the inhibitor
TSP-1 by RRM2 would affect the angiogenic potential of
Knockdown of RRM2 increased TSP-1 and decreased VEGF expression in KB cells Figure 3
Knockdown of RRM2 increased TSP-1 and decreased VEGF expression in KB cells. (A) q-RT-PCR analysis showed 
that RRM2 mRNA was decreased by ~80%, and TSP-1 mRNA was increased by ~5 folds in KB cells at 48 h post-transfection 
with RRM2 siRNA. (B) Western blot analysis showed that TSP-1 protein was significantly increased by ~2.6-fold (KB-W: KB 
cell, Sc-siR: scramble siRNA transfected KB, R2-siR: RRM2 siRNA transfected KB). (C) q-RT-PCR analysis confirmed RRM2 
mRNA was significantly decreased in KB cells at 48 h post-transfection under both normoxia and hypoxia. (D) q-RT-PCR anal-
ysis showed VEGF mRNA in KB cells was decreased after RRM2 knockdown under both normoxia and hypoxia. (E) VEGF in 
condition medium of KB was significantly decreased after RRM2 knockdown under both normoxia and hypoxia. Data was pre-
sented as the mean ± SD of 2–3 independent experiments, *p < 0.05, **p < 0.01, compared with scramble siRNA transfected.Molecular Cancer 2009, 8:11 http://www.molecular-cancer.com/content/8/1/11
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tumors. In vitro, we measured the ability of condition
medium collected from KB-V and KB-M2-D cell lines to
affect endothelial cell motility, a crucial event of the ang-
iogenic process, known to be modulated by the VEGF and
TSP-1 etc [18-20]. Using the Boyden chamber assay, we
identified the HUVEC attracted by condition medium of
KB-M2-D was 78.3 ± 10.7 (mean ± SD), and that attracted
by condition medium of KB-V was 25.6 ± 6.4; statistic
analysis indicated that the condition medium of the KB-
M2-D were significantly more active in stimulating the
migration of HUVEC cells in comparison with that of con-
trol KB-V cells (p < 0.01).
To evaluate the effect of RRM2 on the in vivo angiogenic
potential of tumor cells, we measured the microvascular
density in KB-V and KB-M2-D xenografts. The tumor sec-
tions were used for immunohistochemical analysis for the
endothelial marker: CD31 and the number of CD31 pos-
itive vessels per tumor was assessed. The tumor xenografts
derived from KB-M2-D had a significantly higher number
of CD31 positive vessels as compared to the vector control
KB-V cells (Figure 6a, b). Mean vessel counting per field
was 26 ± 4.2 for KB-V (n = 8) and 37.8 ± 8.4 for KB-M2-D
(n = 8), the difference were significant in statistic (Figure
6c, P < 0.01). Our data indicated that overexpression of
RRM2 positively affects angiogenesis in vivo.
Discussion
RRM2 is well-known as small subunit of RNR, a rate-lim-
iting enzyme for dNDP synthesis required for DNA repli-
cation [1-3]. High RNR enzymatic activity is associated
with tumor progression and resistance to various cellular
stressors such as chemotherapeutic agents and ionizing
radiation [6-8]. Increased RRM2 and RNR enzymatic
activity were reported to present in highly metastatic
tumor cells and tissues [9-11]. Therefore, RRM2 is also an
important therapeutic target for DNA replication-depend-
ent diseases such as cancer. Recently, many studies have
demonstrated that RRM2 plays additional roles in deter-
mining the malignant potential of tumor cells. For exam-
ple, elevated expression of RRM2 has been found to
increase the drug-resistant properties of cancer cells and
Knockdown of RRM2 increased TSP-1 and decreased VEGF expression in LNCaP Cells Figure 4
Knockdown of RRM2 increased TSP-1 and decreased VEGF expression in LNCaP Cells. (A) q-RT-PCR analysis 
confirmed that RRM2 mRNA decreased by ~80%, and TSP-1 mRNA increased by ~8 folds in LNCaP cells at 48 h post-transfec-
tion with RRM2 siRNA. (B) Western blot analysis showed that TSP-1 protein was significantly increased by ~3.4-fold (Ln-Wt: 
LNCaP cell, Sc-siR: scramble siRNA transfected LNCaP, R2-siR: RRM2 siRNA transfected LNCaP). (C) q-RT-PCR analysis 
confirmed that RRM2 mRNA was significantly decreased in LNCaP at 48 h post-transfection under both normoxia and 
hypoxia. (D) q-RT-PCR analysis showed VEGF mRNA in LNCaP cells was decreased after RRM2 knockdown under both nor-
moxia and hypoxia. (E) VEGF in condition medium of LNCaP was significantly decreased after RRM2 knockdown under both 
normoxia and hypoxia. Data was presented as the mean ± SD of 2–3 independent experiments, *p < 0.05, **p < 0.01, com-
pared with scramble siRNA transefected.Molecular Cancer 2009, 8:11 http://www.molecular-cancer.com/content/8/1/11
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significantly enhance the invasive potential of many
human cancer cells [3,9,10,15], whereas knockdown of
RRM2 expression results in the reversal of drug-resistance
and suppressed tumor growth, and decreased metastasis
potential [14,16,25]. Studies have identified that overex-
pression of both RRM1 and RRM2 leads increased RR
activities and expended dNTP pools [[9,13,15], and [26]].
Interestingly, two recent studies have the studies found
that overexpression of RRM1 suppresses invasion and
metastasis formation of tumors through induction of
PTEN pathway [9-11]. These data suggest two subunits of
RNR play opposing roles in tumor progression and malig-
nancy; beside they cooperate in dNTP production.
Tumor angiogenesis is necessary for the growth and
metastasis of many tumors. Potential of angiogenic switch
is a critical character of tumor malignancy [17-19]. Tumor
angiogenesis and metastatic formation are intrinsically
connected [20,27]. Accumulating evidences support
RRM2 possesses oncogene-like properties; it plays a
potential role in tumor malignancy and metastasis. In this
study, we therefore focused on the effect of RRM2 on
tumor angiogenesis. We investigated the effect of overex-
pression of RRM2 on the production of angiogenesis reg-
ulatory factors in human cancer cells. Our study
demonstrated that overexpression of RRM2 decreased the
production of TSP-1 and increased that of VEGF in KB
cells. Because hypoxia is a critical factor regulating VEGF
Overexpression of RRM2 promoted the growth of KB-M2-D in vivo Figure 5
Overexpression of RRM2 promoted the growth of KB-M2-D in vivo. (A) Typical RT-CES traces described that KB and 
KB-M2-D proliferated in an equal rate. CI was recorded every half hour. Each trace for each cell was an average of 4 replicates. 
(B) Tumor growth curves showed that RRM2 significantly promoted KB-M2-D in vivo growth. (C) Overexpression of RRM2 
increased tumor xenografts size of KB-M2-D at the end of experiment. (D) q-RT-PCR analysis confirmed that RRM2, VEGF 
and TSP-1 mRNA was significantly different in KB-V and KB-M2 xenografts. *p < 0.05; **p < 0.01, compared with Kb-V. Data 
expressed was the mean ± SD of 12 mice of two independent experiments.Molecular Cancer 2009, 8:11 http://www.molecular-cancer.com/content/8/1/11
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expression through stabilizing its transcriptional factor
HIF-1 protein and it is also an essential factor for tumor
development [28]. We also examined the effect of RRM2
on VEGF expression under hypoxia condition. The data
demonstrated that under hypoxia condition overexpres-
sion of RRM2 further increased VEGF protein in KB cells.
To further confirm the regulation, we measured TSP-1 and
VEGF expression in KB and LNCaP cells after RRM2
knockdown by its specific siRNA. Contrast to overexpres-
sion of RRM2, we found knockdown of RRM2 expression
caused an increased TSP-1 and decreased VEGF expression
in both KB and LNCaP cells. Considering the potential
therapeutic application of RNA interference for RRM2
such as siRNA, antisense oligo-nucleotide [16,25], our
above finding is potentially important, and it also indi-
cates that the therapy based on RNA interference for
RRM2 may potentially inhibit tumor angiogenesis beside
its known inhibitory effects [16,25]. The changes in the
expression of angiogenic factors: TSP-1 and VEGF induced
by RRM2 in tumor cells did result in increased angiogenic
activity in vitro, as shown by the increased chemotactic
activity for endothelial cells. Moreover, tumors generated
in vivo by RRM2-overexpressing cells showed a higher vas-
cular density compared to controls. We supposed that
higher vascular density might partially contribute to
growth advantage of RRM2-overexpressing cancer cells.
Consistent with what we expected, the increased vascular-
ization caused by overexpression of RRM2 did confer a
growth advantage to RRM2-overexpressing cancer cells.
VEGF is significantly associated with poor outcome in
human various malignancies [29,30]. The increased pro-
CD31 immunohistochemistry assay displayed that overexpression of RRM2 resulted in more vascularized tumor xenografts Figure 6
CD31 immunohistochemistry assay displayed that overexpression of RRM2 resulted in more vascularized 
tumor xenografts. Representative immunohistochemical assay of vascularization of tumor xenografts generated in vivo by 
(A) KB-V and (B) KB-M2-D cells (×100). (C) Semi-quantitative analysis showed that CD31 staining was significantly increased 
in KB-M2D tumor xenografts compared with that of KB-V, *p < 0.05. Values expressed were the mean ± SD of 8 mice of two 
independent experiments.Molecular Cancer 2009, 8:11 http://www.molecular-cancer.com/content/8/1/11
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duction of VEGF is significant for various cancers develop-
ment. Exposure of tumor cells to hypoxia is a common
finding in solid tumors. Hypoxia induces a myriad of
adaptive changes within tumor cells, which result in
increased anaerobic glycolysis, new blood vessel forma-
tion and genetic instability [28]. Consistently, a previous
study by Graff et al [31] also found that elevated RNR
caused by overexpression of RRM2 could overrule long-
lasting arrest of DNA-synthesis after severe hypoxia insult,
and cancer cells with elevated RRM2 were more resistant
to hypoxia. TSP-1 is an important inhibitor of angiogen-
esis, and its suppression is crucial for the angiogenic
switch in many tumor models [[32,33], and [34]]. Addi-
tionally, TSP-1 is an inhibitor of invasion; it inhibits the
activity of matrix metalloproteinase-9 (MMP9), which
causes release of vascular endothelial growth factor
sequestered in the extracellular matrix, thereby increasing
invasion potential [35]. Coincidentally, a recent study of
Duxbury et al [36] also found that overexpression of
RRM2 increased pancreatic adenocarcinoma cellular inva-
siveness and MMP-9 expression.
The earlier study by Wright et al [12,13] reported that
mouse RRM2 synergize with a variety of oncogenes
including h-ras, h-rac, v-src, a-raf, c-myc, etc in cellular
transformation and tumorigenic potential to normal
fibroblast cells through a variety of signal pathways. For
example, cooperation with Ras, overexpression of mouse
RNR small subunit R2 significantly increases membrane-
associated Raf-1 protein and MAPK-2 activity, finally fur-
ther activates MAPK pathway [13]. Oncogenes not only
promote aberrant cellular mitogenesis, but also have an
important impact on tumor formation and growth
through an indirect mechanism, namely, by driving
tumor angiogenesis [20-22]. Oncogenes such as v-myc, c-
jun, v-src  h-ras etc down-regulate the TSP-1 expression
[20-22]. Additionally, some of them – for example, h-ras
and c-myc – also significantly up-regulate VEGF expres-
sion [34]. Contrast to oncogenes, tumor suppressor genes
such as p53, Rb and PTEN etc stimulate TSP-1 expression
[20-22]. Interestingly, our previous study found that in
cancer cells, even without any stress RRM2 and p53R2 are
bound to wild-type p53 protein. In response to UV irradi-
ation, RRM2 and p53R2 dissociate themselves from p53
and form RNR with RRM1 [37]. It is interesting to further
examine whether elevated RRM2 has any impact on p53
function through the protein-protein interaction. Coinci-
dently, we found that knockdown of RRM2 leads a signif-
icantly elevated p53 protein in both KB and LNCaP
(unpublished data); we are focusing on the correlations
among these proteins. Since p53 acts as a negative control-
ler of angiogenesis, and the loss of functional p53 results
in high VEGF and low TSP-1 production, with consequent
increase in angiogenic activity [38]. The mechanisms
through which RRM2 regulate TSP-1 and VEGF expression
requires further investigation.
Conclusion
Overexpression of RRM2 in KB cell suppressed TSP-1
expression, and increased VEGF expression. Conversely,
attenuating RRM2 expression via siRNA resulted in a sig-
nificant increased TSP-1 expression and decreased VEGF
production in both KB and LNCaP cells. Our study dem-
onstrated that overexpression of RRM2 substantially pro-
moted the in vivo growth of tumor cells, and positively
affected the overall angiogenic activity of tumor cells.
Knockdown of RRM2 by RNA interference such as siRNA
may potentially inhibit cancer angiogenesis.
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